Synopsis
In this prospective study on pharmacokinetic parameters (Ktrans & Ve) of renal tumors, we enrolled the patients with five common subtypes of renal tumor - clear cell renal cell carcinoma (ccRCC), papillary renal cell carcinoma (pRCC), chromophobic renal cell carcinoma (cRCC), uroepithelial carcinoma (UEC), and fat poor angiomyolipoma (fpAML) to undergo DCE-MRI pharmacokinetic studies. Our results demonstrated that ccRCC, pRCC, cRCC, UEC and fpAML are pharmacokinetically different (Ktrans & Ve). Ktrans could distinguish ccRCC from non-ccRCC (pRCC & cRCC) and differentiate fpAML with non-ccRCC with high specificity and sensitivity, which probably can facilitate the precise treatment of renal tumors in the future clinical practice.How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords